Anti-IgE monoclonal antibody for the treatment of asthma and other manifestations related to allergic diseases

Sarinho, Emanuel; Cruz, Ãlvaro A.

doi:10.2223/jped.1551

Cited by 9 publications

(4 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The current pharmacological therapy for asthmatic patients includes inhaled short-acting b-agonists (178), long-acting bagonist (179), inhaled corticosteroids (180), systemic corticosteroids (181), leukotriene receptor antagonist (182), and biological agents, mainly monoclonal antibodies, directed against different immunological targets involved in the occurrence and severity of allergic asthma symptoms (183)(184)(185)(186). Among the biological agents currently available for asthma treatment, some of the most used are mepolizumab, reslizumab, and benralizumab, which interfere with the functions of IL-5 and, in the case of the latter, has cytotoxic activity against cells that express the IL-5 receptor; dupilumab, that blocks IL-4 receptor a (187-189); omalizumab, that leads to a reduce binding of IgE to its receptor as well as downregulates the FcϵRI expression (190); and tezepelumab, that blocks TSLP and probed useful in cases of type-2 low asthma (191).…”

Section: Reconsidering Current Treatment Of Asthmamentioning

confidence: 99%

Natural killer T cells in allergic asthma: implications for the development of novel immunotherapeutical strategies

Gutiérrez-Vera,

García-Betancourt,

Palacios

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Allergic asthma has emerged as a prevalent allergic disease worldwide, affecting most prominently both young individuals and lower-income populations in developing and developed countries. To devise effective and curative immunotherapy, it is crucial to comprehend the intricate nature of this condition, characterized by an immune response imbalance that favors a proinflammatory profile orchestrated by diverse subsets of immune cells. Although the involvement of Natural Killer T (NKT) cells in asthma pathology is frequently implied, their specific contributions to disease onset and progression remain incompletely understood. Given their remarkable ability to modulate the immune response through the rapid secretion of various cytokines, NKT cells represent a promising target for the development of effective immunotherapy against allergic asthma. This review provides a comprehensive summary of the current understanding of NKT cells in the context of allergic asthma, along with novel therapeutic approaches that leverage the functional response of these cells.

show abstract

Section: Reconsidering Current Treatment Of Asthmamentioning

confidence: 99%

Natural killer T cells in allergic asthma: implications for the development of novel immunotherapeutical strategies

Gutiérrez-Vera,

García-Betancourt,

Palacios

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Omalizumab also inhibits binding of IgE to FcεRI on dendritic cells and to FcεRII on lymphocytes T and B, eosinophils, and on other cells (Sarinho and Cruz 2006). This binding reduces the expression of receptors on the effector cells.…”

Section: Omalizumabmentioning

confidence: 99%

Monoclonal Antibodies for the Management of Severe Asthma

Rubinsztajn

Chazan

2016

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Asthma is a heterogeneous inflammatory disease. Most patients respond to current standard of care, i.e., bronchodilators, inhaled glucocorticosteroids and other anti-inflammatory drugs, but in some adequate asthma control cannot be achieved with standard treatments. These difficult-to-treat patients would be the target population for new biological therapies. At present, omalizumab is the only biological agent approved for the treatment of early-onset, severe IgE-dependent asthma. It is safe, effective, and well tolerated. Also, discovery of asthma subtypes suggests new treatments. Half of patients with severe asthma have T-helper type 2 (Th-2) inflammation and they are expected to benefit from monoclonal antibody-based treatments. The efficacy of the investigational monoclonal antibody mepolizumab which targets IL-5 has been well documented in late onset non-atopic asthma with persistent eosinophilic airway inflammation. Anti-IL-4 and IL-13 agents (dupilumab, lebrikizumab, and tralokinumab) which block different Th-2 inflammatory pathways and agents targeting the Th-17 inflammatory pathway in severe refractory asthma are under development. In clinical trials, these drugs reduce disease activity and improve lung function, asthma symptoms, and quality of life. However, studies on larger groups of patients are needed to confirm their safety and efficacy.

show abstract

“…The use of monoclonal anti-IgE antibody has not been approved for the treatment of allergic rhinitis, although clinical trials have revealed its efficacy. (55,56)…”

Section: Anti-ige Antibodiesmentioning

confidence: 99%

Rinite alérgica: aspectos epidemiológicos, diagnósticos e terapêuticos

et al. 2008

View full text Add to dashboard Cite

This study was a review of the literature on the epidemiological, clinical, diagnostic and therapeutic aspects of allergic rhinitis. Bibliographic searches were based on the information contained within the Medline, Latin American and Caribbean Health Sciences Literature and HighWire databases, covering the last thirty years and using the following search terms: 'allergic rhinitis', 'epidemiology', 'diagnosis' and 'treatment'. Sixty articles were selected. This study describes the increase in the prevalence of allergic rhinitis, its relationship with asthma, the diagnostic criteria and the treatment. The classification of allergic rhinitis and strategies for its treatment are presented. Therapeutic modalities presented and discussed include the administration of antihistamines, corticosteroids, immunotherapy, anti-leukotrienes, sodium cromoglycate and anti-IgE antibodies, as well as minimizing exposure to inhaled allergens. Finally, the importance of the management of allergic rhinitis in public health is emphasized.

show abstract

Anti-IgE monoclonal antibody for the treatment of asthma and other manifestations related to allergic diseases

Abstract: Objectives: To report on the pharmacology, efficacy and safety of omalizumab , a new option for the treatment of asthma and allergic diseases and the first monoclonal anti-IgE antibody approved for clinical use.

Cited by 9 publications

References 47 publications

Natural killer T cells in allergic asthma: implications for the development of novel immunotherapeutical strategies

Natural killer T cells in allergic asthma: implications for the development of novel immunotherapeutical strategies

Monoclonal Antibodies for the Management of Severe Asthma

Rinite alérgica: aspectos epidemiológicos, diagnósticos e terapêuticos

Contact Info

Product

Resources

About